Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients

Abstract

Objectives

The aim of this study was to evaluate the immunogenicity and safety of the influenza A H1N1/2009 vaccine in children under 9 years old with autoimmune rheumatic diseases (ARD).

Methods

Thirty-eight ARD patients and 11 healthy children received two doses of non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like vaccine. Subjects were evaluated before and 21 days after vaccination. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers (GMT) and factor increases (FI) in GMT were calculated.

Results

Mean ages were comparable between patients and controls. Pre-vaccination SP and GMT were similar in patients and controls (p > 0.05). Three weeks after immunization, SP (81.6% vs. 81.8%, p = 1.0), SC (81.6% vs. 90.9%, p = 0.66), GMT (151.5 vs. 282.1, p = 0.26) and the FI in GMT (16.7 vs. 36.3, p = 0.23) were similar in patients and controls, with both groups achieving an adequate response, according to the European Medicines Agency and Food and Drug Administration standards. Analysis of the possible factors influencing SC showed no difference in demographic data, leukocyte/lymphocyte counts or immunosuppressant use between seroconverted and non-seroconverted patients (p > 0.05). The vaccine demonstrated a satisfactory safety profile in this population.

Conclusions

Two doses of influenza A H1N1/2009 vaccination induced an effective antibody response and caused adverse events in rare instances, suggesting this vaccine is appropriate and can be recommended for this age group.

Keywords

Vaccine pandemic influenza A H1N1 immunogenicity children rheumatic diseases

Get full access to this article

View all access options for this article.

References

McCann

. Should children under treatment for juvenile idiopathic arthritis receive flu vaccination? Arch Dis Child 2007; 92: 366–368.

Bridges

Fukuda

Cox

. Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2001; 50: 1–44.

Nolan

McVernon

Skeljo

. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: A randomized trial. JAMA 2010; 303: 37–46.

Fiore AE, Uyeki TM, Broder K, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1–62. [Erratum, MMWR Recomm Rep 2010; 59: 1147. MMWR Recomm Rep 2010; 59: 993.].

Silva

Terreri

Aikawa

. Vaccination practice in children with rheumatic disease. Rev Bras Reumatol 2010; 50: 351–361.

Aikawa

Campos

Silva

. Glucocorticoid: Major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012; 39: 167–173.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

Petty

Southwood

Manners

. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004; 2: 390–392.

Bohan

Peter

. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344–347.

10.

(Subcommittee for scleroderma criteria) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581–589.

11.

Ozen

Pistorio

Iusan

. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69: 798–806.

12.

EMA. Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. London: European Medicines Agency, 1996. (Publication no. CPMP/BWP/214/96), http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf (accessed February 2011).

13.

EMA. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products, 2004, http://archives.who.int/prioritymeds/report/append/62EMEAguidelines.pdf (accessed February 2011).

14.

USFDA. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. May 2007, http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf (accessed February 2011).

15.

Shoenfeld

Agmon-Levin

. ‘Asia' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4–8.

16.

Aikawa

Campos

Goldenstein-Schainberg

. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2013; 42: 34–40.

17.

Dell'Era

Corona

Dalen

Scala

Principi

Esposito

. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 2012; 30: 936–940.

18.

Guissa

Pereira

Sallum

. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: Reduced immunogenicity in patients under immunosuppressive therapy. Clin Exp Rheumatol 2012; 30: 583–588.

19.

Mathian

Devilliers

Krivine

. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3502–3511.

20.

Caillet

Durrieu

Jacquet

. French Network of Pharmacovigilance Centres. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2011; 67: 649–651.